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DOI 10.1016/j.ccr.2012.03.043SUMMARYEmbryonal rhabdomyosarcoma (ERMS) is an aggressive pediatric sarcoma of muscle. Here, we show that
ERMS-propagating potential is confined to myf5+ cells and can be visualized in live, fluorescent transgenic
zebrafish. During early tumor growth,myf5+ ERMS cells reside adjacent normal muscle fibers. By late-stage
ERMS, myf5+ cells are reorganized into distinct regions separated from differentiated tumor cells. Time-
lapse imaging of late-stage ERMS revealed thatmyf5+ cells populate newly formed tumor only after seeding
by highly migratory myogenin+ ERMS cells. Moreover, myogenin+ ERMS cells can enter the vasculature,
whereas myf5+ ERMS-propagating cells do not. Our data suggest that non-tumor-propagating cells likely
have important supportive roles in cancer progression and facilitate metastasis.INTRODUCTION
Rhabdomyosarcoma (RMS) is a pediatric malignancy that
shares common features with skeletal muscle arrested in embry-
onic development (Xia et al., 2002). The two main subtypes of
pediatric rhabdomyosarcoma, embryonal RMS (ERMS) and
alveolar RMS (ARMS), differ in their clinical, biological, and
molecular characteristics. For example, ERMS and ARMS can
be distinguished based on histology and have different long-
term prognoses, with ERMS patients having better overall
outcome than ARMS patients. These divergent clinical features
likely reflect the use of different molecular programs that lead
to transformation. For example, we have identified that the
RAS pathway is active in a majority of human ERMS (HettmerSignificance
Tumor-propagating potential is not found in all malignant cells,
are largely incapable of remaking tumor and yet constitute a m
cells in tumor growth, including dissemination and metastasis
myogenin-positive ERMS cells lack tumor-propagating poten
vasculature. Slow-movingmyf5+ ERMS-propagating cells are r
entiated ERMS cells. This finding may explain the clinical obse
outcome in human ERMS and suggests that differentiated tum
680 Cancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc.et al., 2011; Langenau et al., 2007). By contrast, 85% of ARMS
cells have recurrent chromosomal translocations that juxtapose
PAX3 or PAX7 with the forkhead transcription factor (FKHR) (Xia
et al., 2002). Finally, it is likely that ERMS and translocation-posi-
tive ARMS arise in different cell types that eventually undergo
transformation. Keller et al. (2004) found that PAX3-FKHR+
ARMS can arise from Myf6-expressing myoblast cells but not
dermamyotome or satellite cells that express Pax7. By contrast,
ERMS can arise from either satellite cells or myoblasts that even-
tually reinitiate molecular programs found in satellite cells (Rubin
et al., 2011). Despite elegant studies defining possible cells of
origin in RMS, identification of an ERMS-propagating cell that
is required for continued tumor growth in vivo has not been
described in mice or humans.and, in most cancers, cells with more differentiated features
ajority of the tumor mass. A role for differentiated malignant
, has not been fully explored. We find that mid-differentiated
tial yet are responsible for local invasion and can enter the
ecruited to new sites of tumor growth after seeding by differ-
rvation that Myogenin positivity correlates with poor clinical
or cells play critical roles in metastasis.
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malignances, and in some tumors, this potential is confined to
a molecularly definable cell population that can be enriched by
cell surface markers. For example, in acute myeloid leukemia,
a rare CD34+CD38 cell enriches for leukemia-propagating
potential while in breast cancer CD44+CD24low/expression is
associated with tumor-propagating potential (reviewed in Da-
lerba et al., 2007). Molecularly defined, rare CD133+ tumor-prop-
agating cells have also been identified in a subset of gliomas and
exhibit striking differences in response to nitric oxide and
hypoxia inducible factor signaling when compared to more
differentiated tumor cells (Eyler et al., 2011; Li et al., 2009).
Thus, it is likely that many tumors contain hierarchically orga-
nized cell subpopulations that retain the capacity to remake
tumor and yet give rise to differentiated tumor cell progeny.
One might expect that selection would favor the evolution of
tumors with high numbers of tumor-propagating cells at a cost
of differentiated cell types. Paradoxically, however, in most
malignancies, tumor-propagating cells are far less abundant
than differentiated tumor cells that are incapable of remaking
tumor. These data suggest that differentiated tumor cells may
provide important supportive roles in overall growth and mainte-
nance. To date, a role for differentiated, non-tumor-propagating
ERMS cells has yet to be fully explored.
Stem cells often reside in distinct niches in normal tissue, and
their functions are exquisitely controlled by local factors
secreted by supporting cells. For example, hematopoietic stem
cells (HSCs) have been shown to home to niches within the
calvarium that are tightly associated with osteoblasts (Lo Celso
et al., 2009). These and other niche-associated cells presumably
provide paracrine-signaling factors to recruit and maintain these
cells in a specific niche. Unlike other tissues, the muscle stem
cell niche is defined by juxtaposition of satellite cells next to
differentiated muscle fibers, and their numbers and differentia-
tion capacity are controlled by complex signaling pathways
regulated by mature muscle cells (reviewed in Bentzinger et al.,
2012). Despite a large body of data defining stem cell niches in
normal tissue, few studies have identified tumor-specific niches
and/or regions of compartmentalized tumor cell function and
fewer still have used microscopic imaging to directly visualize
tumor-propagating cells within live animals. In one example,
Sipkins et al. (2005) used a combination of multiphoton and
confocal microscopy to image the HSC niche in the calvarium
of mice and demonstrated that these sites can attract multiple
tumor cell types; however, it is unknown if these malignant
cells are capable of reinitiating tumors. In ERMS, as with most
solid tumors, it is unknown whether tumor-propagating cells
reside in distinct regions within the tumor mass and whether
the more differentiated cells play a role in promoting tumor
progression.
Here, we utilize a transgenic zebrafishmodel of ERMS to iden-
tify the tumor-propagating cell in this disease and to define the
functional consequences of tumor cell heterogeneity within live
animals. Because ERMS cell subpopulations can be fluorescent
labeled based on myogenic factor expression, ERMS cell
subtypes can be visualized in live animals and the processes
of cell growth, division, and local dissemination can be visualized
as dynamic processes in live animals. Our data provide an expla-
nation for the large number of non-tumor-propagating cells inestablished cancers and reveal an important supportive role
for differentiated tumor cell types in local dissemination and
metastasis.
RESULTS
Imaging Distinct Stages of ERMS Growth
Externally visible ERMS can develop as early as 10 days of life in
zebrafish injected with rag2-KRASG12D (Langenau et al., 2007),
and >80% of ERMS develop in the tail musculature (n > 50). To
assess how tumors initiate and evolve in zebrafish ERMS, we
injected a-actin-GFP transgenic zebrafish at the one-cell stage
of development with rag2-dsREDexpress and rag2-KRASG12D
(Figures 1A–1F), facilitating imaging of ERMS cells in relation to
normal muscle. Microinjection of multiple transgenes into one-
cell-stage animals leads to cointegration and coexpression in
animals that develop ERMS (Langenau et al., 2008). This
approach provides a robust method to create mosaic transgenic
animals with fluorescently labeled ERMS cell subpopulations
(Langenau et al., 2007).
Sequential confocal imaging over several days showed that
ERMS forms in a choreographed and stereotypical manner
(Figures 1A–1F and 1J–1M). Specifically, dsRed+ ERMS mono-
nuclear cells arise at the extreme outer borders of the myotome
segments and move toward the midline where they are initially
unable to bypass the horizontal myosepta—a single cell layer
that separates myotome segments (Figure 1A; stage 1, n = 7).
After several days, a subset of cells cross the horizontal myo-
septa and take up residence between normal muscle fibers
within the newly colonized myotome segment (stage 2; Figures
1B and 1C; n = 5). Differentiated ERMS cells that express both
rag2-dsREDexpress and a-actin-GFP can move laterally into
neighboring muscle segments by transiting through the collagen
matrix of the myoseptum (n = 6; Figures 1D–1F; Movie S1 avail-
able online) or stream into new myotome segments by growing
past the edge of myoseptum (n = 3, early stage 3). The collagen
matrix of the muscle myoseptum is a cell-impermeable barrier
that is the site of muscle attachment in teleost fish and is similar
in function to tendons in mouse and humans. Late-stage ERMS
cells undergo rapid loss of fibers, breakdown of normal muscle
architecture including collagen remodeling, and development
of mononuclear tumor cells, reminiscent of the spindle variant
of human ERMS.
Neovascularization is a hallmark of cancer and an ideal surro-
gate for assessing tumorigenicity. To assess when KRASG12D-
expressing cells are transformed, we monitored neovasculariza-
tion in fli1-GFP transgenic animals that were injected at
the one-cell stage of life with rag2-KRASG12D and rag2-
dsREDexpress. Animals were monitored for tumor growth by
confocal microscopy beginning at 10 days of life (n = 22; Figures
1G–1I). ERMS at stage 1 failed to recruit new vasculature (n = 0
of 3), but stage 2 and early stage 3 ERMS had begun to recruit
new vasculature (n = 8 of 8; Figure 1H) with new branches arising
from both the intersegmental vessels and vertebral artery. By
late stage 3, ERMS developed intricate networks of new vessels
(n = 11 of 11; Figure 1I). Our imaging studies define distinct
stages of ERMS growth and suggest that RAS-expressing cells
become fully transformed by stage 2 of tumor development
(Figures 1J–1M).Cancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc. 681
Figure 1. Visualizing Distinct Stages of
Embryonal RMS Growth
(A–F) rag2-dsRED-labeled ERMS arising in
a-actin-GFP transgenic zebrafish. The same
animal imaged at 6, 9, and 12 days postfertilization
(dpf) is shown in (A), (B), and (C), respectively. A
representative zebrafish where dsRED+ ERMS
cells have already bypassed the horizontal my-
oseptum and migrated into new segments that
were previously free of tumor (F, stage 3) at 13, 18,
and 24 dpf is shown in (D), (E), and (F), respec-
tively. The horizontal myoseptum is denoted by
white arrows.
(G–I) fli1-GFP transgenic control animal (G)
compared with a rag2-dsRED-labeled ERMS
arising in fli1-GFP transgenic zebrafish at early
stage 2 (H) or a late stage 3 (I).
(J–M) Schematic of stages of ERMS growth.
Scale bars in the upper panels of (A) through (C),
500 mm. Scale bars in the lower panels of (A)
through (C) and in (D) through (I), 100 mm.
See also Movie S1.
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Labeled ERMS Cell Subpopulations
Previous experiments in zebrafish have identified an ERMS cell
subpopulation that had superior tumor-propagating potential
when compared to other tumor-derived cells. This ERMS-prop-
agating cell was rag2-dsREDexpress+/a-actin-negative and ex-
pressed high levels ofmyf5, c-met, andm-cadherin—markers of
satellite and early muscle progenitor cells (Langenau et al.,
2007). MYF5 is highly upregulated in human ERMS compared
to both translocation positive ARMS and normal muscle (Zibat
et al., 2010) and in comparing zebrafish ERMS to normal muscle
(Langenau et al., 2007). To directly assess whether myf5 labels
distinct ERMS cell subpopulations,myf5-GFP/myosin light chain
2-mCherry (mylz2) syngeneic animals were created by four
rounds of outcrossing to CG1 syngeneic animals (Smith et al.,
2010) and injected at the one-cell stage with rag2-KRASG12D.
myf5-GFP transgenic animals exhibit green fluorescent protein
(GFP) expression in early somitogenesis and later in satellite cells
and early muscle progenitor cells (Chen et al., 2007; Seger et al.,
2011) while the mylz2 promoter drives expression in differenti-
ated muscle cells (Ju et al., 2003; Smith et al., 2010). Fluores-
cent-labeled ERMS cell subpopulations were isolated from
double transgenic animals by fluorescence-activated cell sorting
(FACS). Reanalysis of sorted cells by FACS confirmed that
ERMS contained four distinct populations of cells (purity >
87% and viability > 97%).
To verify that discrete fluorescent-labeled ERMS cell subpop-
ulations were molecularly distinct, sorted cell populations were682 Cancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc.assessed for gene expression differences
based on microarray (Figure 2A; Table
S1) and real-time PCR (Figures 2B
and S1). Gene expression analysis was
completed on FACS-sorted ERMS cells
derived from serially passaged tumors,
ensuring that fluorescent-labeled cells
were tumor derived. Microarray analysis
confirmed that each cell subpopulation
exhibited wide differences in geneexpression. Subsequent real-time PCR analysis established
that the myf5-GFP+/mylz2-mCherry-negative cells expressed
high levels of myf5, c-met, and m-cadherin but not pax7a,
pax7b, or differentiated markers (Figures 2B and S1). By
contrast, mylz2-mCherry+ ERMS cells expressed high levels of
mature muscle markers including myod, myogenin, troponin I
fast-twitch isoform 2 (tnni2a), a-actin 1b (acta1b), ventricular
myosin heavy chain-like (vmhcl), actin-related protein 2/3
complex subunit 5B (arpc5b), carboxypeptidase vitellogenic-
like (cpvl), and chemokine (C-X-C motif) receptor 4b (cxcr4b).
Finally, the double-negative cell population comprised predom-
inantly blood cells that express myeloid-specific peroxidase
(mpx) and lymphocyte-specific protein tyrosine kinase (lck). Our
data confirm that fluorescent-labeled ERMS cell subpopulations
can be prospectively isolated to relative purity following FACS
and are molecularly distinct.
Given that FACS could identify unique ERMS cell subpopula-
tions that exhibited wide differences in gene expression, we
questioned whether these cells also differ in rates of proliferation
and cellular turnover. Proliferation was assessed at 6 hr following
intraperitoneal injection of EDU into ERMS-affected animals
(Figures 2C–2E and S1). myf5-GFP+/mylz2-mCherry-negative
cells (24.1% ± 4.8%) incorporated EDU over a 6 hr pulse,
whereas differentiated ERMS cells that express mylz2-mCherry
were far less proliferative (8.9% ± 5.0%; p < 0.00001). By
contrast, following 3-day administration of EDU, all fluorescent-
labeled ERMS cell subfractions exhibited equal proliferative
capacity, suggesting that myf5-GFP+/mylz2-mCherry-negative
Figure 2. Fluorescent Transgenic Approaches Identify Discrete and Molecularly Definable ERMS Cell Subpopulations in myf5-GFP/mylz2-
mCherry Transgenic Fish
(A) Heat map showing differential gene expression between FACS-sorted ERMS cell subpopulations isolated from serially passagedmyf5-GFP/ mylz2-mCherry
ERMS (microarray log fold-change > 1.5).myf5-GFP+/mylz2-mCherry-negative (G+),myf5-GFP+/mylz2-mCherry+ (G+R+),myf5-GFP-negative/mylz2-mCherry+
(R+), and double negative (DN).
(B) Quantitative real-time PCR of sorted ERMS cell subpopulations. Expression values, ±1 SD.
(C and D) Confocal images of EDU-stained sections from serially passaged myf5-GFP+/mylz2-mCherry+ ERMS. Tumor regions with large numbers of either
myf5-GFP+ (C) ormylz2-mCherry+ ERMS cells (D). Blue denotes DAPI+ nuclei, and white denotes EDU+ nuclei. Yellow arrows indicate EDU-labeled cells. Scale
bar, 25 mm.
(E) Quantification of EDU incorporation over a 6 hr EDU pulse. Data for myf5-GFP+/mylz2-mCherry-negative ERMS cells are denoted by green bars, data for
myf5-GFP+/mylz2-mCherry+ cells are indicated by yellow bars, and data formyf5-GFP-negative/mylz2-mCherry+ cells are indicated by red bars. Three individual
tumors shown as well as cumulative data across all tumors (Total). *p < 0.00001. Error bars, ±1 SD.
(F) FACS plot of serially passaged myf5-GFP/mylz2-mCherry ERMS.
(G–J) Gated ERMS cells assessed for DAPI and AnnexinV-APC staining (double negative, DN) (G); myf5-GFP+/mylz2-mCherry-negative (G+) (H); myf5-GFP+/
mylz2-mCherry+ (G+R+) (I); and myf5-GFP-negative/mylz2-mCherry+ (R+) (J). Live cells are shown within the DAPI-negative/AnnexinV-negative gates.
See also Figure S1 and Table S1.
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addition to striking differences in cell proliferation betweenERMS
cell subpopulations, myf5-GFP+/mylz2-mCherry+ cells had
higher levels of apoptotic cellular turnover when compared with
myf5-GFP+/mylz2-mCherry-negative and myf5-GFP-negative/
mylz2-mCherry+ cells (p < 0.01, Fisher’s exact test; Figures 2F–
2J). Taken together, our fluorescent transgenic approach iden-
tifies unique ERMS cell subpopulations that have different fluo-
rescent reporter expression, divergent gene expression profiles,
and varied capacities for proliferation and apoptosis.
myf5-GFP+ Cells Are the ERMS-Propagating Cell
Population
To assess if myf5-GFP transgene expression enriches for
ERMS-propagating potential, cells were isolated from transplant
animals that developed myf5-GFP+/mylz2-mCherry+ ERMS
(Figures 3A–3G) and subjected to two rounds of FACS in thepresence of propidium iodide or DAPI to isolate highly purified
and viable cells (Figures 3H–3K; 87.7%–99.7% purity and
>98% viability). ERMS cell subpopulations were introduced into
CG1 syngeneic recipient animals at limiting dilution (Figure 3L–
3R), and animals were assessed for engraftment from 10 to
120 days posttransplantation (Table 1). All animals developed
ERMSbefore45daysposttransplantation, confirming that slower
cycling ERMS-propagating cell types would not bemissed in our
analysis. In three ERMS tumors tested, the tumor-propagating
activitywas confined to themyf5-GFP+/mylz2-mCherry-negative
cell subpopulation (Table 1),with an average frequencyof 1 in 146
cells capable of reinitiating tumors in recipient animals (range 1 in
87–245, 95% confidence interval). By contrast, only 1 in 4,206
myf5-GFP+/mylz2-mcherry+ cells were capable of inducing
tumors (range 1 in 1,550 to 11,409, 95% confidence interval,
p = 3.38e-15 when compared to ERMS-propagating activity in
myf5-GFP+/mylz2-mcherry-negative cells). Of 61 animals, noneCancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc. 683
Figure 3. ERMS-Propagating Cells Express myf5-GFP but Not the mylz2-mCherry Differentiated Muscle Marker
(A) Schematic of experimental design.
(B–D) A primary ERMS arising in syngeneic myf5-GFP/mylz2-mCherry transgenic zebrafish (35 dpf). Broken black line denotes tumor area.
Cancer Cell
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Table 1. Limiting Dilution Cell Transplantation Identifies that




Cell # G+ G+R+ R+ Neg G+
1,000 6 of 6 2 of 7 0 of 6 0 of 7 6 of 6
10 5 of 9 0 of 9 0 of 8 0 of 10 7 of 8
10 0 of 8 0 of 8 0 of 9 0 of 7 0 of 10
TPC # 1 in 140** 1 in 3,461 NA NA 1 in 67
95% CI 59–329 872–13,740 NA NA 31–143
ERMS #2 2
Transplants
Cell # G+ G+R+ R+ Neg
1,000 6 of 6 0 of 6 0 of 6 0 of 6
10 4 of 7 2 of 10 0 of 10 0 of 10
10 1 of 8 0 of 9 0 of 10 0 of 8
TPC # 1 in 109** 1 in 3,495 NA NA
95% CI 44–270 808–15,120 NA NA
ERMS #3 2
Transplants
Cell # G+ G+R+ R+ Neg
1,000 2 of 3 0 of 2 0 of 3 0 of 4
10 8 of 9 0 of 8 0 of 8 1 of 8
10 1 of 8 0 of 9 0 of 9 0 of 9
TPC # 1 in 159** NA NA 1 in 4,840
95% CI 63–401 NA NA 632–37,094
Asterisks denote significant differences in tumor-propagating cell
number (TPC #) between myf5-GFP+/mylz2-mCherry-negative and
double-positive ERMS cells (**p < 0.00001). Neg, negative; NA, not appli-
cable; 95% CI, 95% confidence interval.
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negative/mylz2-Cherry+ cells (lower bound for ERMS-propa-
gating potential was 1 in >5,969 cells). In total, we observed
a remarkable 28- to >40-fold enrichment of tumor-propagating
potential within our myf5-GFP+/mylz2-mCherry-negative cell
type when compared with other sorted ERMS cell subpopula-
tions. Similar results were also observed in primary ERMS.
Specifically, three primary ERMS tumors were isolated from
20- to 30-day-old larval zebrafish, pooled, and fluorescent-
labeled ERMS cell subpopulations were isolated by FACS. Of
eight animals, three engrafted disease from 102 myf5-GFP+/
mylz2-mCherry-negative cells, whereas the remaining ERMS
cell subpopulations could not transfer disease at this cell dose
(0 of 23, purity 83%–98% and viability > 98.6%, p = 0.012,
Fisher’s exact test). These results further support our finding
that themyf5-GFP+/mylz2-mCherry-negativepopulation ishighly
enriched for ERMS-propagating activity.(E–G) Fluorescent-labeled ERMS engraft into syngeneic secondary recipient ani
(H–K) FACS plots of fluorescent-labeled ERMS cells isolated from secondary rec
(L–R) Transplantation of myf5-GFP+/mylz2-mCherry-negative FACs sorted cells
(S–U).
Hematoxylin- and eosin-stained sections (C, F, M, and T) and FACS (D, G, N, and
and 100 mm (for C, F, M, and T).To assess the long-term tumor-propagating potential of the
myf5-GFP+/mylz2-mCherry-negative ERMS cells, cells were re-
isolated from transplant recipient animals (Figure 3N) and intro-
duced into CG1, syngeneic recipient animals (>78.9% purity
and 96% viable; Figures 3O–3R). Again, the myf5-GFP+/mylz2-
mCherry-negative cell subpopulation was capable of remaking
ERMS (Figure 3S–3U; Table 1). Histological analysis showed
that primary and serially transplanted ERMS arising from myf5-
GFP+/mylz2-mCherry-negative cell populations have similar
morphology and overall proportions of fluorescent-labeled
ERMS cell subpopulations (Figures 3C, 3D, 3F, 3G, 3M, 3N,
3T, and 3U).
Visualizing myf5-GFP+ ERMS-Propagating Cells In Vivo
To assess whether myf5-GFP+ ERMS cells could be directly
visualized in live animals, rag2-dsREDexpress and rag2-
KRASG12D were coinjected into one-cell-stage myf5-GFP
transgenic animals and assessed by confocal microscopy.
Discrete myf5-GFP+ tumor cells could be readily identified by
confocal imaging with a majority of myf5-GFP+ ERMS cells
coexpressing both GFP and dsREDexpress (97.5 ± 2.9%; n =
568 cells counted in three animals). Moreover, myf5-GFP+ early
muscle progenitor cells from control animals were relatively rare
(n = 3 [animals]; 2.3 ± 2.3 cells per imaging field), whereasmyf5-
GFP+ cells were abundant in ERMS (n = 3; 194.2 ± 23.7 cells per
field, t test, p = 0.0002). Taken together, our data suggest that
a vast majority of myf5-GFP+ cells contained within the bound-
aries of the ERMS mass are tumor derived.
To further refine the ERMS cell subpopulations for imaging
studies, triple fluorescent transgenic ERMS animals were
created by microinjecting myogenin-H2B-RFP, mylz2-lyn-cyan,
and rag2-KRASG12D into one-cell-stage myf5-GFP transgenic
animals (Figures 4A–4C). Histone fusion proteins are long lived
and confined to the nucleus, whereas lyn-cyan encodes for
membrane localized blue fluorescent protein. Because trans-
genes cointegrate as concatamers (Langenau et al., 2008),
ERMS cells coexpress all three transgenes and label distinct
tumor cell compartmentsassociatedwith stagesofmuscledevel-
opment (Figure S2). In normal development,myf5 is expressed in
satellite cells and early muscle progenitor cells, myogenin is ex-
pressed in committed, mid-differentiated muscle myoblasts,
and mylz2 is expressed in differentiated myoblasts. Transgenic
reporters have been described for all three of these promoters,
and each drives expression within the correct cellular compart-
ments during normal muscle development (Chen et al., 2007;
Duet al., 2003; Juet al., 2003).Moreover, geneexpressionstudies
confirm that these promoters drive correct tissue-specific gene
expression in ERMS (Figure S2), and additional cell transplanta-
tion experiments establish that myf5-GFP+/myogenin-negative
cell types exclusively retain ERMS-propagating potential (Fig-
ure S2). For example, 4 of 18 animals engrafted ERMS from 102
myf5-GFP+/myogenin-H2B-RFP-negative sorted ERMS cellsmals when transplanted with unsorted primary ERMS cells.
ipient fish following two rounds of FACS.
induced ERMS in tertiary transplant animals (L–R) and quaternary recipients
U) of primary and serially passaged ERMS. Scale bars, 2 mm (for B, E, L, and S)
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Figure 4. myf5-GFP+ ERMS-Propagating Cells Are Dynamically Reorganized during Tumor Growth
(A) Schematic of the experimental design.
(B) A myf5-GFP transgenic animal injected at the one-cell stage of life with rag2-KRASG12D, myogenin-H2B-RFP, and mylz2-lyn-cyan with triple fluorescent-
labeled ERMS at 16 days of life.
(C) A merged confocal image of the boxed region shown in (B).
(D) Control myf5-GFP transgenic animal injected with myogenin-H2B-RFP and mylz2-lyn-cyan. myf5-GFP+ muscle precursor cells are denoted by green
arrowheads.
(E–G) Representative image of an ERMS-affected zebrafish labeled withmyf5-GFP,myogenin-H2B-RFP, andmylz2-lyn-cyan at stages 1, 2, and 3, respectively.
Green arrowheads denote myf5-GFP+ cells, whereas red arrowheads denote mononuclear myogenin-H2B-RFP+ ERMS cells.
(H) Late stage 3 ERMS from a triple fluorescent-labeled animal.
(I and J) Boxed regions in (H) imaged at higher magnification show regional partitioning of differentiated cells (I) compared with myf5-GFP+ ERMS-propagating
cells (J).
(K) Quantification of myf5-GFP+ cells during stages of ERMS growth when compared to control animals.
(L) Quantification of mononuclear myogenin-H2B-RFP+ cells during stages of ERMS growth when compared to control animals.
Cancer Cell
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types could not induce tumors, regardless of whether they ex-
pressedmyf5-GFP (n = 0 of 32, p = 0.013, Fisher’s exact test).
Confocal imaging of fluorescent-transgenic ERMS fish that
express myf5-GFP/myogenin-H2B-RFP/mylz2-lyn-cyan easily
identified myf5-GFP+ cells, of which a small subset coexpress
myogenin-H2B-RFP (Figure 4C). Some myogenin-H2B-RFP+
cells with nuclear fluorescent protein expression fail to express
either myf5-GFP or mylz2-lyn-cyan, indicating that these cells
aremost similar tomidmyoblast stages.Gene expression studies
confirm thatmyogenin-promoter expression drives H2B-fluores-
cent protein expression in a subset of myosin-heavy-chain-ex-
pressing muscle cell populations, implying that these represent
differentiated cell types (Figure S2). Nearly all mylz2-lyn-cyan+
cells coexpress myogenin-H2B-RFP (99.5% ± 1%; n = 8
ERMS, n > 1,700 cells counted), reflecting that H2B-fluorescent
protein expression persists in more differentiated ERMS cells.
myf5-GFP+ cells Are Reorganized into Discrete
Compartments during Late-Stage Tumor Growth
We next wanted to define the location of ERMS cell subpopula-
tions during various stages of tumor growth. myf5-GFP trans-
genic animals were injected with rag2-KRASG12D, myogenin-
H2B-RFP, and mylz2-lyn-cyan and imaged by confocal
microscopy starting at 10 days of life. Stage 1 ERMS exhibited
greatly expanded numbers ofmyf5-GFP+ cells when compared
to control animals and were confined to regions immediately
adjacent to muscle fibers (Figures 4D–4G and 4K). Mononuclear
myogenin-H2B-RFP+ and double-positive myogenin-H2B-
RFP+/ mylz2-lyn-cyan+ ERMS cells were not observed in stage
1 ERMS; however, they were detected by stage 2 and increased
in number as tumors progressed to stage 3 (Figures 4F–4I and
4L). By late stage 3 ERMS, myf5-GFP+ cells lost fiber contacts
and began to populate discrete portions of the tumor that were
physically separated from more differentiated myogenin-H2B-
RFP- and mylz2-lyn-cyan-expressing ERMS cells (Figures 4H–
4J and 4M). The myf5-GFP+ cells were often located within
different myotome segments compared to differentiated ERMS
cell subpopulations; however, regional partitioning of cells based
on differentiation status was also observed within a single
myotome segment and in transplanted animals (Figure S2), con-
firming that compartmentalization did not result from physiolog-
ical constraints imposed during development but rather was an
intrinsic property of ERMS growth.
Human ERMS Cells Are Also Compartmentalized Based
on Myogenic Factor Expression
To assess whether human RMS cells also contain distinct
regions of tumor cells based on myogenic factor expression,
primary human ERMS and xenografted human ERMS derived
from RD and SMS-CTR cell lines (Linardic et al., 2005) were as-
sessed for myogenic marker expression, including Myogenin,(M) Quantification of regional compartmentalization of ERMS cells based on diffe
contain higher percentages of myf5-GFP+ ERMS-propagating cells compared t
differentiated.
Error bars in (K–M), ±1 SD. Scale bar, 500 mm for (B) and 50 mm for (C–J).
See also Figure S2.PAX7, and MYOD. Distinct regions of high and low Myogenin-
expressing cells were seen in a vast majority of primary tumor
samples (n = 12 of 14, p < 0.03, Student’s t test) and were
present in all xenograft tumors (n = 7, six regions per tumor,
p < 0.02, Students’s t test; Figure 5 and Figure S3; Table S2).
By contrast, most ARMS cells expressed Myogenin, and its
expression was not confined to specific areas within the tumor
mass (n = 10; range = 79%–99%), suggesting that regional par-
titioning of tumor cells based onMyogenin expression is specific
to ERMS. We also stained four primary human ERMS tumors for
PAX7 and identified regions of high and low expression in two of
the four tumors. In one ERMS sample, expression was diffuse
while the other tumor was PAX7 negative, indicating that not all
primary ERMS cells express PAX7. Unfortunately, MYF5 anti-
bodies have not been developed to detect human protein within
paraffin-embedded sections, precluding analysis of less differ-
entiated regions contained within the tumors.myogenin+ ERMS Cells Are Highly Migratory and
Precede the Recruitment ofmyf5+ ERMS-Propagating
Cells into Newly Colonized Areas of Growth
Having established that the myf5-GFP-expressing ERMS cell
population contains tumor-propagating activity, we wanted to
assess if these cells also promote invasive tumor growth. Multi-
photon intravital microscopy recordings frommyf5-GFP/myoge-
nin-H2B-RFP or myf5-GFP/myogenin-H2B-Amcyan transgenic
tumor zebrafish revealed that myf5-GFP+ single-positive
ERMS cells were largely stationary and displayed only confined
crawling movements (Figures 6A–6F and S4; Movies S2, S3, S4,
and S5). In contrast, myogenin+ ERMS cells were robustly
migratory and had the ability to invade across myotome
segments through a normally impenetrable collagen matrix.
Cells that expressed lower amounts of the H2B-fluorescent
fusion protein were orderly arranged along the direction of
muscle fibers, had uniform nuclear shape, and did not show
any motility (Movies S2 and S3), suggesting that these were
differentiated tumor cells of which a subset had undergone
fusion (Figure 6F, right).
ERMS cell subpopulations also differ in their proliferative
capacity. Primary ERMS cells from myf5-GFP+/myogenin-H2B-
RFP+ animals were pulsed with EDU for 6 hr and then sectioned
and assessed for EDU incorporation (Figures 6G–6I).myf5-GFP+
ERMS cells were highly proliferative (39.4% ± 9.4%; n = 3),
whereas myf5-GFP-negative/myogenin-H2B-RFP+ cells rarely
proliferated (2.6% ± 3.8%; n = 3, p = 0.0001). In vivo multiphoton
imaging of transplant and primary ERMS confirmed that
myf5-GFP+/mylz2-negative ERMS-propagating cells are highly
proliferative, with 27 of 90 GFP+ cells dividing into two daughter
cells (n = 3 tumors). Multiphoton imaging revealed that resting
myf5-GFP+ ERMS cells are elongated (Figure 6J) and then round
up in shape just prior to cell division (Figure 6K). Following this
dynamic shape change, myf5-GFP+ ERMS cells quickly dividerentiation status in late stage 3 tumors (n = 3). Green bars denote regions that
o white bars where myf5-GFP+ cells are less abundant and conversely more
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Figure 5. Human Embryonal RMS Exhibit Regional Portioning of Cells Based on Myogenic Factor Expression
(A–D) Primary human ERMS.
(E–L) RD human cell lines (E–H) or human RAS-transformed myoblasts (I–L) introduced into SCID/beige mice.
(M–O) Primary human ARMS. Hematoxylin/Eosin-stained sections (A, E, I, and M) and anti-Myogenin immunohistochemistry performed on adjacent sections
(B, F, J, and N). Regions containing high numbers of Myogenin+ cells are denoted by red outline, while regions with low numbers of Myogenin+ cells are denoted
by black outline (B, F, and J). ARMS did not show regional portioning based on Myogenin staining (N). Magnified views of areas with high concentrations of
Myogenin+ cells (C, G, K, and O) or areas with low or absent expression (D, H, and L).
(P–Q) Quantification of regional compartments in primary andmetastatic human RMS (P) and in mice xenografted with human RD and SMS-CTR ERMS cells and
humanRAS-transformedmyoblasts (myoblasts, in Q). Numbers in (Q) denote tumors arising in separate animals. Blue bars denote areas with high percentages of
Myogenin+ cells compared to areas with low numbers of cells (red bars). Green bars denote diffuse and ubiquitous expression of Myogenin within ARMS. Error
bars, ±1 SD. Scale bars, 50 mm (for A, C–E, G–I, K–M, and O) and 200 mm (for B, F, J, and N).
See also Figure S3 and Table S2.
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Dynamic In Vivo Imaging of ERMSinto two GFP-labeled daughter cells (Figures 6L–6M). Subse-
quently, these daughter cells begin to reacquire parental
morphology (Movie S6), reminiscent of normal myf5-GFP+
muscle precursors. By contrast, 0 of 90mylz2+ cells proliferated
over this time, regardless of whether they expressedmyf5-GFP.688 Cancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc.To further visualize the dynamic movements of ERMS cells
in vivo, late stage 3 triple transgenic ERMS affected animals
were serially imaged over 16 hr to capture cell movements
(Figures 7A–7H; Movie S7). As was seen in our multiphoton
imaging, myf5-GFP+ cells that lack differentiated marker
Figure 6. myf5-GFP+ ERMS-Propagating Cells Are Slow Moving but Highly Proliferative whilemyogenin-H2B-RFP+ Cells Do Not Divide but
Are Highly Migratory
(A–E) Multiphoton recording of a stage 3 ERMS arising inmyf5-GFP/myogenin-H2B-RFP transgenic zebrafish (B and C) Magnified view of the boxed region in (A)
showing myf5-GFP+ (B) or myogenin-H2B-RFP+ ERMS cells (C).
(D and E) Tracks of cell movement over the 6.7-hr observation period. The same areas are shown as in (B) and (C), respectively.
(F) Mean track velocities of representative cell types contained within the tumor mass. *p < 0.001.
(G and H) EDU staining of double transgenic myf5-GFP+/myogenin-H2B-RFP+ primary zebrafish ERMS (35 dpf). Confocal image of a tumor section with high
numbers ofmyf5-GFP+ ERMS cells (G) compared to a section with high numbers ofmyogenin-H2B-RFP+ cells (H). White denotes nuclei that have incorporated
EDU. EDU incorporation into myf5-GFP+ or myogenin-H2B-RFP+ ERMS cells denoted by green or red arrows, respectively.
(I) Quantification of proliferation over the 6 hr EDU pulse. myf5-GFP+/myogenin-H2B-RFP-negative (green bars), double positive (yellow bars), and myf5-GFP-
negative/ myogenin-H2B-RFP+ (red bars). Error bars, ±1 SD. Asterisk denotes significant differences, *p = 0.0001.
(J–M) Static images of a myf5-GFP+ ERMS cells dividing. Scale bars, 50 mm (for A, G, and H), 25 mm (for B–E), and 15 mm (for J–M).
See also Figure S4 and Movies S2, S3, S4, S5, and S6.
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Dynamic In Vivo Imaging of ERMSexpression move only locally within the tumor and exhibit
regional crawling movements, whereas myogenin-H2B-RFP+/
mylz2-lyn-cyan-negative cells are highly motile and could be
easily visualized migrating into adjacent nonaffected normal
tissue (Figures 7A–7D; Movie S7). By contrast, differentiated
ERMS cells that express myogenin-H2B-RFP and mylz2-lyn-
cyan are largely stationary.
To investigate which ERMS cells were the first to migrate into
unaffected tissue, we conducted serial imaging experiments
over longer observation intervals, focusing on regions that
were adjacent to expanding tumor. Serial confocal imaging of
fluorescent ERMS fish over several days revealed that myoge-
nin-H2B+ ERMS cells precede the recruitment of myf5-GFP+
cells into newly colonized areas of tumor growth (n = 7; Figures
7I, 7J, and S4). Not only do fluorescent-labeled myogenin-
H2B+ ERMS cells move locally within the tumor, but they alsoenter the vasculature (Movie S8). A small portion of myogenin-
H2B-RFP+/myf5-GFP-negative cells were associated with
vasculature and could invade neovascular beds in fli1-GFP
transgenic animals (Figures 7K and 7L). To verify the fidelity of
H2B-fluorescent labeling of ERMS cell subfractions and to
directly visualize if myf5-GFP+ ERMS cells can enter the vascu-
lature, we induced ERMS in stable transgenic animals that
express myf5-GFP/flk1-mCherry by coinjecting both rag2-
KRASG12D and myogenin-H2B-Amcyan. As was seen using
the H2B-RFP transgenic reporter, we found that myogenin-
H2B-Amcyan+ cells are highly migratory (Movies S4 and S5),
were the first cell type to colonize new areas of tumor growth,
and could be observed transiting the vasculature (Figures 7M
and 7N; Movies S5 and S9). By contrast,myf5-GFP+ ERMS cells
exhibited reduced motility when compared with myogenin+
ERMS cells and were never observed entering the vasculatureCancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc. 689
Figure 7. myf5-GFP+ ERMS-Propagating Cells Are Recruited to New Areas of Tumor Growth Only after Seeding bymyogenin+ ERMS Cells
(A–H) Time-lapse images of myf5-GFP transgenic animal injected with rag2-KRASG12D, myogenin-H2B-RFP and mylz2-lyn-cyan. Panels are merged image
planes taken every hour. myogenin-H2B-RFP+ cells migrate into normal tissues over time (white boxed region). Magnified views of time-lapse images doc-
umenting thatmyf5-GFP+ cells are largely stationary whilemyogenin-H2B-RFP+ cells are highly migratory andmigrate away fromGFP+ cells (denoted by arrows
in E–H).
(I and J) Serial imaging of a myf5-GFP transgenic animal injected with rag2-KRASG12D and myogenin-H2B-RFP shown at 14 and 17 dpf, respectively. White
boxes denote a region that initially contained only myogenin-H2B-RFP+ cells (I) but was later colonized by myf5-GFP+ cells (J).
(K and L) ERMS developing in a fli1-GFP transgenic animal injected with rag2-KRASG12D, myogenin-H2B-RFP, and mylz2-lyn-cyan. (K) Merged z-stacks
showing three myogenin-H2B-RFP+ cells associated with and inside fli1-GFP+ vessels, which was confirmed by imaging a single image plane at higher
magnification (L, white arrowhead).
(M and N) ERMS developing in a flk1-mCherry transgenic animal injected with rag2-KRASG12D and myogenin-H2B-cyan showing four cells entering the
vasculature (white arrowheads in M) and a single plane image showing two cells transiting into the vasculature at higher magnification (white arrowheads in N).
Scale bar, 50 mm (for A–H, K, L, and N) and 100 mm (for I, J, M).
See also Figure S4 and Movies S7, S8, and S9.
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Dynamic In Vivo Imaging of ERMS(n = 10 animals). Again, slow-moving myf5-GFP+ cells were
found in newly colonized regions only after initial invasion by
myogenin+ ERMS cells.
DISCUSSION
Myf5 as a Marker of ERMS-Propagating Cells
The limiting dilution cell transplantation studies outlined here
confirm the existence of a highly purified and molecularly defin-
able ERMS-propagating cell that expresses myf5, m-cadherin,
and c-met but not differentiated muscle markers. The myf5-
GFP+ ERMS-propagating cell gives rise to all the other differen-
tiated ERMS cells contained within the tumor mass and exhibits
enhanced proliferative capacity as assessed by EDU incorpora-
tion and direct in vivo cell imaging. These results are in keeping690 Cancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc.with our previous work showing that ERMS-propagating activity
was largely confined to the rag2-dsRED+/a-actin-negative
ERMS cell population that preferentially expressed myf5 and
other activated satellite cell markers (Langenau et al., 2007).
However, rag2-dsRED+/a-actin-negative ERMS cells exhibited
only amodest 3-fold enrichment for tumor-propagating potential
when compared to rag2-dsRED+/alpha-actin+ ERMS cells
(Langenau et al., 2007). By contrast, experiments outlined here
using new fluorescent transgenic reporter lines and syngeneic
zebrafish show that the myf5-GFP+/mylz2-negative ERMS cells
exhibit a remarkable 28- to >40-fold enrichment of tumor-prop-
agating potential when compared to other ERMS-derived cell
populations.
Myf5 is a myogenic regulatory factor related to MyoD and
has important roles in muscle development. For example,
Cancer Cell
Dynamic In Vivo Imaging of ERMSMyoD/Myf5-deficient mice lack muscle, while deficiencies in
only one of these genes does not affect muscle specification
(Rudnicki et al., 1993), suggesting important and yet redundant
functions of these genes in development. It has also been shown
that Myf5 is highly expressed in activated satellite cells and has
important roles in postnatal muscle regeneration in response to
injury (Cooper et al., 1999; Gayraud-Morel et al., 2009; Ustanina
et al., 2007), suggesting that Myf5 may regulate self-renewal in
normal muscle satellite cells. Microarray analysis and cross-
species comparisons have shown that MYF5 is upregulated in
both zebrafish and human ERMS but not translocation-positive
ARMS (Langenau et al., 2007; Zibat et al., 2010), and recent
work fromRubin et al. (2011) has shown thatMyf5 is differentially
expressed in murine ERMS regardless of which muscle cell
subpopulation is initially targeted for transformation. These
results suggest that Myf5 gene programs are likely reinitiated
in transformed cells and may have important roles in driving
ERMS growth. By contrast, translocation-positive ARMS fail to
expressMYF5, precludingMYF5 marker expression as an iden-
tifying characteristic of ARMS-propagating cells and raising the
interesting possibility that the molecular mechanisms regulating
tumor-propagating potential differ between molecular subtypes
of RMS. Given the critical roles of the Myf5 transcription factor in
muscle development and regeneration in mice, it will be impor-
tant to assess if myf5 is a marker of ERMS-propagating cells
or if it plays a regulatory role in ERMS self-renewal and growth.
Regional Partitioning of ERMS Cells Based
on Differentiation Status
Evidence in solid tumors to support a discrete, specialized
microenvironment that augments tumor growth and proliferation
is now just beginning to emerge. For example, tumor-propa-
gating cells, including those of glioblastomas, have been shown
to reside in a vascular niche that promotes both their mainte-
nance and their ability to divide and produce daughter cells
capable of inducing tumors (reviewed by Gilbertson and Rich,
2007). In other solid tumors arising in skin, prostate, and breast,
tumor stromal fibroblasts also serve an essential role inmaintain-
ing a favorable microenvironment for tumor growth and expan-
sion. For example, work by Orimo et al. (2005) has shown that
stromal fibroblasts associated with invasive breast carcinoma
cells can promote tumor growth and angiogenesis through
secretion of SDF-1. In normal muscle, stem cell numbers are
exquisitely regulated by paracrine factors like Wnt5a (Pole-
sskaya et al., 2003), Myostatin (McCroskery et al., 2003), and
Notch ligands (Conboy et al., 2003). Many of these factors are
secreted by normal fibers that can sense injury and elicit recruit-
ment and expansion of muscle progenitors that are required for
regeneration. Thus, mature muscle provides a supportive micro-
environment that facilitates homeostatic regulation of muscle
stem cells. In our zebrafish ERMS model, we document that
myf5-GFP+ ERMS-propagating cells are initially juxtaposed to
muscle fibers in an expanded muscle satellite/progenitor cell
niche, suggesting that early stage ERMS cells cannot escape
the constraints of muscle architecture or are held in check by
local secreted factors emanating from normal muscle. By the
late stages of ERMS growth, ERMS-propagating cells are reor-
ganized and take up residence in defined regions within the
tumor mass. Following this regional partitioning of ERMS cells,mid-differentiated myogenin+ ERMS cells show enhanced
migratory capability and move away from the ERMS-propa-
gating cells fromwhich they had arisen. Thesemid-differentiated
myogenin+ ERMS cells are highly migratory, seed new areas of
tumor growth, and cease to move once they turn on differenti-
ated muscle markers including muscle myosin light chain.
Such biologically constrained characteristics of ERMS cells
would ensure that tumor-propagating cells remain confined to
regionally defined areas and do not compete with differentiated
ERMS cells for local resources including growth factors and
oxygen. The extent to which regional partitioning of tumor cells
occurs in other solid tumors is unknown; however, assuming
this phenomenon is found in diverse cancer types, it will be
important to determine if regional partitioning of tumor cells
provides protective advantages to tumor-propagating cells,
facilitating the retention of a small number of cancer cells that
evade treatment and eventually give rise to disease relapse.
A Role for Differentiated, Non-Tumor-Propagating Cells
in Facilitating Tumor Growth and Metastasis
Myogenin immunohistochemical reactivity found in >80% of
RMS cells distinguishes patients with poor clinical outcome
(Heerema-McKenney et al., 2008), suggesting that Myogenin+
cells have a unique role in RMS progression and metastasis. In
our model, myogenin-H2B+ cells arise from myf5-GFP+
ERMS-propagating cells, lack tumor-propagating potential,
and are the first cell type to migrate into new areas of tumor
growth. A subset of myogenin+ ERMS cells infiltrate blood
vessels—a first step toward metastasis—and are also the first
to colonize new areas of tumor growth, only to be infiltrated later
by slow-migratingmyf5+ ERMS-propagating cells. Our work rai-
ses the interesting possibility that differentiated, non-ERMS-
propagating cells may create a supportive environment that
augments growth and is responsible for local tumor invasion.
For example, it is possible that once mid-differentiated
myogenin+ cells infiltrate new areas of growth, that they secrete
factors that recruit slow-movingmyf5+ ERMS-propagating cells,
facilitating tumor spread. Alternatively, it is possible that
myogenin+ cells break down collagen and cell-cell contacts,
acting as trailblazers to establish migratory tracks that allow
slow-moving myf5+ ERMS-propagating cells to transit into
newly forming tumor. Our work also highlights that metastatic
capacity and tumor-propagating potential need not be confined
to the same tumor cell subpopulations, but rather that local infil-
tration and metastasis may be facilitated by differentiated, non-
tumor-propagating cells. We expect that these same principles
may be more broadly applicable to a diversity of cancers,
accounting for why tumors retain large numbers of differentiated
cell types that themselves are incapable of reconstituting tumor.
Our findings of a myf5+ ERMS-propagating cell population
and a myogenin+ migratory population both contributing to
tumorigenesis may have profound therapeutic implications.
Instead of targeting only tumor-propagating cells for destruction,
drug design should also take into account themechanisms regu-
lating the homeostasis of more differentiated tumor cells and
their nonproliferative roles in regulating growth. Moreover, ther-
apies that focus on modulating the differentiation status of
ERMS cells should attempt to force the conversion of tumor-
propagating cells into cells with terminally differentiatedCancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc. 691
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Dynamic In Vivo Imaging of ERMSmyoblast characteristics that are incapable of recreating tumor,
cannot migrate, and fail to enter into the vasculature.
EXPERIMENTAL PROCEDURES
Study Approval
These studies were approved by the Massachusetts General Hospital
Subcommittee on Research Animal Care under protocol #2011N000127
(zebrafish), the Duke University Institutional Animal Care & Use Committee
under protocol A 036-03-02 (mouse), and the Partners Human Research
Committee under protocol #2009-P-002756 (human). Samples were obtained
from the Pathology Department ofMassachusetts General Hospital. Use of de-
coded, paraffin-embedded human tissue samples does not require informed
consent.
Animals
CG1-strain (Smith et al., 2010), a-actin-GFP (Higashijima et al., 1997), myf5-
GFP (Chen et al., 2007), fli1-GFP (Lawson and Weinstein, 2002), flk1-mCherry
(Wang et al., 2010), and mylz2-mCherry transgenic zebrafish (Smith et al.,
2010) have been reported previously.
The rag2-KRASG12D, rag2-dsREDexpress, myogenin-H2B-RFP, myoge-
nin-H2B-Amcyan, and mylz2-lyn-cyan constructs were microinjected into
one-cell-stage zebrafish singly (rag2-KRASG12D injected into myf5-GFP/
mylz2-mCherry syngenic zebrafish, 60 ng/ml) or as combinations with linear-
ized DNA at a final combined concentration of 120 ng/ml essentially as
described (Langenau et al., 2008).
FACS and ERMS Cell Transplantation
FACS analysis and ERMS cell transplantation were completed essentially as
described elsewhere (Smith et al., 2010; Langenau et al., 2007). Sort gates
were placed based on wild-type control fish and myf5-GFP+, mylz2-
mCherry+, or mylz2-lyn-cyan+ ERMS. DAPI, propidium iodide, or TOPRO3
was used to isolate viable cells. ERMS tumors were double sorted to obtain
pure, viable cell populations. Sort purity was assessed after two rounds of
sortingwhen possible. Following limiting dilution cell transplantation into nonir-
radiated syngeneic CG1-recipient animals, fish were analyzed for fluorescent
tumor engraftment from 10 to 120 days posttransplantation. Tumor-propa-
gating potential was quantified using the Extreme Limiting Dilution Analysis
software (http://bioinf.wehi.edu.au/software/elda/). A subset of transplanted
fishwas sectioned and stainedwith hematoxylin and eosin to confirm the pres-
ence or absence of ERMS.
Immunohistochemistry, EDU Staining, and Annexin V Staining
Paraffin embedding and sectioning, cryostat sectioning, and immunohisto-
chemical analysis were performed essentially as described elsewhere
(Langenau et al., 2007; see also Supplemental Experimental Procedures).
EDU staining was performed using the Click-iT Alexa Fluor 647 imaging kit
(Invitrogen). Annexin analysis for apoptotic cells was performed via FACS
using annexin V conjugated to Alexa Fluor 647 (Invitrogen).
Gene Expression Analysis
Total RNA was isolated from AB-strain embryos 6 and 24 hr postfertilization
and FAC-sorted ERMS cell subpopulations (TRIzol, GIBCO/BRL) in the pres-
ence of glycol blue. Quantitative real-time PCR utilized gene-specific PCR
primers (Supplemental Experimental Procedures), and expression was
normalized to 18 s and b-actin controls to obtain relative transcript levels using
the 2-DDCT method. Relative gene expression was normalized within individual
samples, and cumulative transcript expression across the four ERMS cell
subpopulations was set to 25. Samples were assessed in relation to embryos
6 and 24 hr postfertilization to ensure that results for 2-DDCT results for any
given gene were not lower than 10-fold expression found in normal develop-
ment. Microarray experiments were completed essentially as described (fold
change cutoff > 1.5-fold log scale; Langenau et al., 2007). Microarray data
have been deposited into the GEO database (GSE32425).
Laser Scanning Confocal Microscopy and Dual Photon Imaging
Larval zebrafish were anesthetized in Tricaine and embedded in a single drop
of low melt 1% agarose on a glass bottom petri dish (No 1.5, Mat Tek Corpo-692 Cancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc.ration). Each petri dish was supplemented with fish water and imaged using an
inverted Pascal or LSM510 Zeiss laser scanning confocal microscope or an
upright Ultima IV multiphoton microscope (Prairie Technologies). Quantifica-
tion was completed by counting the total numbers of fluorescent-labeled
ERMS cell subpopulations contained in two 250 3 150 mm areas per animal
(Figures 4K and 4L; control, n = 7; stage 1, n = 3; stage 2, n = 4; stage 3,
n = 7). Because regional niches can be compartmentalized within a single
myotome segment, a smaller area was assessed for total numbers of myf5-
GFP+ and myogenin-H2B-RFP+ ERMS cells (50 3 50 mm2 area, six areas
per tumor; Figure 4M).
For cell tracking, sequences of image stacks were transformed into
maximum intensity-projected movies using Imaris 7.1 software (Bitplane)
and exported asQuicktimemovies. Manual two- or three-dimensional tracking
was performed using the manual tracking plugin in ImageJ or using Imaris 7.1.
Annotation and further processing ofmovies was completed using ImageJ and
Quicktime 7.SUPPLEMENTAL INFORMATION
Supplemental Information includes nine movies, two tables, four figures, and
Supplemental Experimental Procedures and can be found with this article
online at doi:10.1016/j.ccr.2012.03.043.
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